Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index; 22 of the 31 sources its claims cite were checked for support.

Efficacy and safety of GLP-1 receptor agonists on weight management and metabolic parameters in PCOS women: a meta-analysis of randomized controlled trials

Open access
Lin, Shike, Deng, Yan, Huang, Jing, Li, Meiyan, Sooranna, Suren Rao, Qin, Minzhen, Tan, Bing · 2025 · Scientific Reports

Abstract

This meta-analysis aimed to evaluate the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1RAs) when compared to metformin and placebo in the management of body weight, glucose homeostasis and hormone levels in women polycystic ovary syndrome (PCOS). A systematic search of "PubMed", "EMBASE", "Cochrane Library", "Web of Science" and "Google Scholar" was conducted up to October 2024 for randomized controlled trials involving adult women with PCOS treated with GLP-1RAs compared to metformin or placebo. The primary outcomes were changes in body mass index (BMI), body weight, waist circumference (WC), waist-to-hip ratio (WHR) and abdominal girth (AG). Secondary outcomes included glucose homeostasis (fasting glucose, fasting insulin, OGTT results and HOMA-IR), hormone levels (DHEAS, SHBG, total and free testosterone and FAI), lipid profiles (total cholesterol, HDL, LDL and triglycerides) and safety. GLP-1RAs significantly reduced BMI, body weight, WC, WHR and AG (P < 0.0001 in all cases). For glucose homeostasis, GLP-1RAs significantly reduced fasting insulin, glucose level at 2 h after OGTT, and HOMA-IR. There was also a reduction in HDL. All the other parameters measured were unchanged. In addition, GLP-1RAs increased nausea (P = 0.02), vomiting (0.04) and dizziness (0.03). GLP-1RAs effectively reduced body weight, BMI and insulin resistance in patients with PCOS, although they were accompanied by nausea, vomiting and dizziness. Further studies are needed to explore their long-term effects on glucose homeostasis and lipid profiles.

Overview

CoChat Summary

TL;DR

In this meta-analysis of 13 RCTs in adult women with PCOS, GLP-1 receptor agonists significantly reduced BMI, body weight, waist circumference, waist-to-hip ratio, abdominal girth, fasting insulin, 2-h post-OGTT glucose/insulin, and HOMA-IR compared with metformin or placebo. Benefits were accompanied by increased nausea, vomiting, and dizziness, while overall hormone and most lipid outcomes were largely unchanged.

Key findings

  • Anthropometric outcomes improved significantly: BMI MD −1.59 (95% CI −2.07 to −1.10; P < 0.0001; 11 studies, 349 vs 310 subjects), body weight MD −3.57 (95% CI −5.15 to −1.99; P < 0.0001; 10 studies), WC MD −4.97 (95% CI −5.56 to −4.37; P < 0.0001), WHR MD −0.03 (95% CI −0.03 to −0.03; P < 0.0001), and AG MD −2.05 (95% CI −2.93 to −1.16; P < 0.0001).
  • Glucose homeostasis was mixed: fasting glucose was not significantly reduced overall (MD −0.12; 95% CI −0.28 to 0.04; P = 0.14), but 2-h post-OGTT glucose (MD −0.54; 95% CI −1.01 to 0.07; P = 0.02), fasting insulin (MD −1.40; 95% CI −2.65 to −0.15; P = 0.03), 2-h post-OGTT insulin (MD −27.88; 95% CI −38.58 to −17.17; P < 0.0001), and HOMA-IR (MD −0.58; 95% CI −0.98 to −0.19; P = 0.004) were reduced.
  • Overall hormone levels showed no significant changes for DHEAS, SHBG, total testosterone, free testosterone, or FAI; HDL was reduced (MD −0.02; 95% CI −0.04 to −0.01; P = 0.0001), while total cholesterol, LDL, and triglycerides were not significantly changed overall.
  • Safety: GLP-1RAs increased nausea (OR 3.07; 95% CI 1.56–6.03; P = 0.02), vomiting (OR 2.05; 95% CI 1.04–4.06; P = 0.04), and dizziness (OR 5.58; 95% CI 1.23–25.22; P = 0.03); stomachache was lower (OR 0.15; 95% CI 0.03–0.66; P = 0.01), and diarrhea, constipation, bloating, fatigue, headache, and insomnia were not significantly increased.

Methods

  • Systematic review and meta-analysis of RCTs identified from PubMed, EMBASE, Cochrane Library, Web of Science, and Google Scholar up to October 2024; 13 RCTs met inclusion criteria, including 397 participants receiving GLP-1RAs, 330 receiving metformin, and 68 receiving placebo.
  • Eligible participants were adult women aged 18–45 years with PCOS; interventions were GLP-1RAs (semaglutide, liraglutide, exenatide) versus metformin or placebo, with follow-up of at least 12 weeks.
  • Mean differences or odds ratios with 95% CIs were calculated using RevMan 5.0; random-effects models were used when I² > 50%, fixed-effects models when I² < 50%; subgroup analyses compared metformin versus placebo controls, and funnel plots assessed publication bias.

Limitations

  • The authors state high heterogeneity across studies, variability in populations, interventions, and methodologies, and insufficient detail on concurrent background interventions, limiting stratified or sensitivity analyses.
  • The authors note inconsistent effects across outcomes, especially fasting glucose and hormone levels, and caution in interpreting overall effectiveness despite funnel plots showing no publication bias.
  • Evident from the text: several analyses were small or based on single studies, some subgroup confidence intervals were very wide, and some reported P values/confidence intervals appear inconsistent (e.g., 2-h post-OGTT glucose CI crossing zero with P = 0.02; FAI CI and P value mismatch), while six studies had high risk of performance bias.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41598-025-99622-4

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 A PRISMA flow diagram for the literature selection.
Fig. 1 A PRISMA flow diagram for the literature selection.CC BY-NC-ND · PubMed Central
Fig. 2 A bias assessment of this study. (A) Risk of bias bar. (B) Risk of bias summary.
Fig. 2 A bias assessment of this study. (A) Risk of bias bar. (B) Risk of bias summary.CC BY-NC-ND · PubMed Central
Fig. 3 A meta-analysis of BMI changes found in this study (A), body weight changes (B), WC (C), WHR (D) and AG (E).
Fig. 3 A meta-analysis of BMI changes found in this study (A), body weight changes (B), WC (C), WHR (D) and AG (E).CC BY-NC-ND · PubMed Central
Fig. 4 Meta-analysis of the fasting glucose (A), glucose at 2 h (B), fasting insulin (C), insulin at 2 h (D) and HOMA-IR (E) levels found in this study.
Fig. 4 Meta-analysis of the fasting glucose (A), glucose at 2 h (B), fasting insulin (C), insulin at 2 h (D) and HOMA-IR (E) levels found in this study.CC BY-NC-ND · PubMed Central
Fig. 5 Meta-analysis of the DHEAS (A), SHBG (B), total testosterone (C), free testosterone (D) and FAI (E) levels found in this study.
Fig. 5 Meta-analysis of the DHEAS (A), SHBG (B), total testosterone (C), free testosterone (D) and FAI (E) levels found in this study.CC BY-NC-ND · PubMed Central
Fig. 6 Meta-analysis of the total cholesterol (A), HDL (B), LDL (C) and TG (D) levels found in this study.
Fig. 6 Meta-analysis of the total cholesterol (A), HDL (B), LDL (C) and TG (D) levels found in this study.CC BY-NC-ND · PubMed Central
Fig. 7 Meta-analysis of nausea (A), vomiting (B), diarrhea (C), constipation (D), stomachache (E), bloating (F), dizziness (G), fatigue (H), headache (I) and insomnia (J) found in this study.
Fig. 7 Meta-analysis of nausea (A), vomiting (B), diarrhea (C), constipation (D), stomachache (E), bloating (F), dizziness (G), fatigue (H), headache (I) and insomnia (J) found in this study.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

13 Valid · 2 Not valid · 4 Not checked · 141 Own results and interpretations

101 more claims

Create a free account to see all 160 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 30
  • Probably not a substantial claim. 32
  • The quote only partly states this claim. 3

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

5 of 11 · the rest aren’t loaded

6 more findings

Create a free account to see every finding of this check.

See all findings — free account

Citations

Cites

Show all 46 references

Cited by

See all 35

Metadata

Authors
Lin, S., Deng, Y., Huang, J., Li, M., Sooranna, S. R., Qin, M., & Tan, B.
Affiliations
  • Youjiang Medical College for Nationalities (CN)
  • Chinese University of Hong Kong (HK)
  • Imperial College London (GB)
  • Affiliated Hospital of Youjiang Medical University for Nationalities (CN)
Corresponding author
  • Qin, Minzhen
  • Tan, Bing
Venue
Scientific Reports
Published
2025-05-13
Volume
15
Issue
1
Pages
16512-16512
ISSN
2045-2322 (ISSN-L)
OpenAlex
W4410332077
Cited by
35
References
46
Citations by year
2026: 33 · 2025: 2
FWCI
4.80
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
GLP-1 receptor agonists, polycystic ovary syndrome, weight management, insulin resistance, glucose homeostasis, metformin, body mass index, waist circumference, lipid profile, HDL cholesterol, adverse effects, nausea, testosterone
MeSH terms
Glucagon-Like Peptide-1 Receptor Agonists, Adult, Blood Glucose, Body Weight, Female, Humans, Hypoglycemic Agents, Insulin, Metformin, Polycystic Ovary Syndrome, Body Mass Index, Randomized Controlled Trials as Topic, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of GLP-1 receptor agonists on weight management and metabolic parameters in PCOS women: a meta-analysis of randomized controlled trials. https://app.cochat.ai/papers/10.1038/s41598-025-99622-4
The paper
Lin, S., Deng, Y., Huang, J., Li, M., Sooranna, S. R., Qin, M., & Tan, B. (2025). Efficacy and safety of GLP-1 receptor agonists on weight management and metabolic parameters in PCOS women: a meta-analysis of randomized controlled trials. Scientific Reports. https://doi.org/10.1038/s41598-025-99622-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.